Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF. Stephen Hodi, Jedd D. Wolchok, Wen-Jen Hwu et al.|Journal of Clinical Oncology|2016Cited by 754
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Scot Ebbinghaus et al.|Clinical Cancer Research|2018Cited by 311
Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.F. Stephen Hodi, Jedd D. Wolchok, Antoni Ribas et al.|Journal of Clinical Oncology|2014Cited by 40
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Clinical Cancer Research|2018Cited by 38
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.Richard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Journal of Clinical Oncology|2014Cited by 35